Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionTandem Diabetes Care Inc. Common Stock (TNDM)
Fair value
Not available
ACCE price target
$16.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 13 Oct 2026, 00:00 CEST.
Price used: $17.43 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
28
out of 100
Analysts
52% buy
25 covering
P/E
0.0x
forward 117.6x
1-year return
+18.9%
Dividend yield
0.00%
Tandem Diabetes Care Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Tandem Diabetes Care makes insulin pump systems, including the t:slim X2 and Mobi pumps and the Control-IQ automated insulin delivery algorithm that adjusts basal dosing from continuous glucose monitor readings. Its moat is mostly in software and integration: Control-IQ and the Dexcom partnership sit on top of a installed base of pump users, and gross margin of 56.0% reflects that mix. Revenue growth of 5.8% is modest, and the company is still loss-making at the operating line with a -5.4% operating margin and a -48.0% return on equity, so the case rests on margin expansion as volume grows. The screen flags it as expensive on earnings, with a forward P/E of 117.6 against no trailing earnings, and it carries a low score of 29/100 with no index membership. It merits a deeper look mainly to see whether the gross margin strength can convert to operating profit, and what the pace of Mobi adoption and new algorithm releases does to that conversion.